secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K/A
Filed at:   2022-06-06T23:59:59+00:00
Accession:  0001564590-22-022527
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD adopts bylaw amendment facilitating acquisition by Athene Parent via tender offer and merger
--------------------------------------------------------------------------------

- Bylaw amendment adopted May 27, 2022, makes Nevada control share statutes inapplicable to the merger agreement with Athene Parent and Merger Sub.
- Amendment enables cash tender offer for all outstanding TXMD common stock and subsequent merger.
- This 8-K/A corrects item number from 1.01 to 5.03; no disclosure changes from the original June 3, 2022 filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459022022527/0001564590-22-022527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459022022527/txmd-8ka_20220527.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-022527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer